Record royalties drive growth while US patent battles persist
- Halozyme's main engine is ENHANZE, a drug delivery enzyme used in ten commercial partner products.
- Total revenue grew 39% year over year in Q3 2026 to $493 million.
- Royalty revenue reached a record $341 million in Q3 2026.
- The company won a key European patent injunction against Merck but faces US appeals until 2028.
- Management estimates about 66% of projected royalties from currently launched products will arrive from 2026 through 2032.
Royalties still have runway
Halozyme is a picks-and-shovels biotech. It does not need to build every drug itself. It licenses delivery technology to larger drug companies, then collects fees, milestones, and royalties when those partners succeed.
The core bull case gained more momentum in Q3 2026. Royalty revenue rose 44% year over year to a record $341 million. Management raised full-year guidance and added new ENHANZE target nominations from major partners like argenx and Johnson & Johnson. With 13 ENHANZE programs expected in the clinic by year-end, the company has plenty of future revenue drivers.
Capital returns are also in full swing. Halozyme is aggressively deploying its $1 billion buyback plan, which can lift per-share results if the core business keeps growing.
The bear case remains tied to litigation and early-stage platforms. While Halozyme secured a European injunction against Merck for patent infringement, US appeals will drag on until roughly 2028. Furthermore, investors still need proof that newer platforms like Hypercon and Aerocon can become commercial royalty machines.
Licensing shots, not selling drugs
ENHANZE is Halozyme's main product platform. It uses rHuPH20, an enzyme that temporarily opens space under the skin so large drug doses can be injected under the skin instead of through a long IV infusion. Partners pay upfront fees, development and sales milestones, buy bulk rHuPH20, and pay royalties on approved products.
The best part of the model is operating leverage. Royalties can grow as partners sell more of their drugs, while Halozyme does not carry the full cost of large global sales teams for those drugs. Royalties remain the biggest revenue stream and continue to grow faster than total company revenue.
Product sales are the second stream. They include proprietary products like Hylenex and XYOSTED, bulk rHuPH20 sold to partners, and device-related product sales. This stream can jump around because partner ordering patterns can change from quarter to quarter.
Collaborative revenue is the lumpiest stream. It includes upfront fees and milestone payments tied to partner progress. Deals across new modalities add promise, but the exact economics are still partly unknown.
What Halozyme owns
ENHANZE
The core drug delivery platform. It powers ten commercial partner products and remains the main source of royalty growth.
DARZALEX FASPRO and DARZALEX SC
Janssen's multiple myeloma franchise is Halozyme's largest disclosed royalty driver.
VYVGART Hytrulo
argenx's autoimmune drug is a fast-growing ENHANZE product that continues to see rapid sales adoption.
Phesgo
Roche's breast cancer product adds another large ENHANZE royalty stream. It continues to grow as a reliable contributor.
Hypercon
Hypercon is a high-concentration drug delivery platform from the Elektrofi acquisition. Vertex and Oruka are partners, but Phase I starts are expected in the first half of 2027.
Aerocon
Formerly known as Surf Bio, Aerocon is another high-concentration platform. It extends the long-term platform story but still needs clearer clinical timing.
Hylenex and XYOSTED
These are Halozyme's own marketed products. They help diversify revenue, but the company page story is mostly about partner royalties.
Revenue mix
Mix is based on Q3 2026 total revenue of $493 million. Royalties make up the vast majority of current sales, reaching $341 million in the quarter.
What could break the thesis
Merck patent case stretches in the US
High impact · Medium oddsHalozyme won a Dutch Patent Court injunction against Merck over alleged use of MDASE technology in subcutaneous Keytruda. However, adverse validity decisions on US patents mean the appeals process will persist into 2028, creating long-term uncertainty.
Partner sales slow down
High impact · Medium oddsHalozyme depends on partners such as Janssen, argenx, and Roche to sell the drugs that generate royalties. If DARZALEX SC, VYVGART Hytrulo, or Phesgo slow, Halozyme cannot fix that by hiring its own sales force.
Hypercon and Aerocon do not scale
Medium impact · Medium oddsThe company guided the first Phase I clinical studies for Hypercon to start in the first half of 2027. Commercial proof for these newer platforms is years away.
Supply chain bottlenecks
Medium impact · Low oddsHalozyme relies on a limited number of third-party manufacturers for bulk rHuPH20 and other key components. If supply misses partner needs, product sales and partner launches could be delayed.
IRA policy changes after 2028
Medium impact · Low oddsCMS proposed rules for the Medicare Drug Price Negotiations Program could impact price negotiations for 2029 and beyond, affecting long-term ENHANZE royalty streams.
In one breath
What does Halozyme actually do?
Halozyme licenses drug delivery technology to other drug companies. Its main platform, ENHANZE, helps some medicines move from IV infusion to faster under-the-skin injection.
Why are royalties so important for HALO?
Royalties are Halozyme's largest and fastest-growing revenue stream. In Q3 2026, royalty revenue rose 44% year over year to a record $341 million.
What is the Merck lawsuit about?
Halozyme says Merck used its patented subcutaneous delivery technology in the development of subcutaneous Keytruda. Halozyme won an injunction in Europe, but US appeals are ongoing.
Is Halozyme only an ENHANZE company?
ENHANZE is still the main value driver. Halozyme is also building Hypercon and Aerocon, two high-concentration delivery platforms, but those platforms still need clinical starts and commercial proof.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Halozyme Therapeutics, Inc. in Finn's Biotechnology industry ranking.

